Aller­goOn­col­o­gy: Lessons Learned from the Aller­gy-Glioblas­toma Connection

This pre­sen­ta­tion delves into the fas­ci­nat­ing inter­sec­tion of aller­gy and oncol­o­gy, with a par­tic­u­lar focus on glioblas­toma. We will define the field of Aller­goOn­col­o­gy, describ­ing the cur­rent inter­face between aller­gol­o­gy and oncol­o­gy and dis­cussing var­i­ous path­ways involved in the asso­ci­a­tion between aller­gy and glioblastoma.

We will delve into our recent work demon­strat­ing the pro­tec­tive role of aller­gic air­way inflam­ma­tion against glioblas­toma pro­gres­sion in a murine mod­el, and its impli­ca­tions on sys­temic and local immu­ni­ty. Inves­ti­gat­ing how aller­gic inflam­ma­tion delays glioblas­toma pro­gres­sion in mice reveals intri­cate immune mech­a­nisms, includ­ing the tran­scrip­tion­al repro­gram­ming of microglia and the poten­ti­a­tion of local and adap­tive sys­temic immu­ni­ty (Doi: 10.1111/all.15545) .

Addi­tion­al­ly, we will dis­cuss our col­lab­o­ra­tive efforts between the Euro­pean Acad­e­my of Aller­gy and Clin­i­cal Immunol­o­gy (EAACI) and the Euro­pean Asso­ci­a­tion of Neu­ro-Oncol­o­gy (EANO), aim­ing to refine the clas­si­fi­ca­tion of aller­gic dis­eases and gliomas for enhanced research in Aller­goOn­col­o­gy (Doi: 10.1111/all.15994).

Through these dis­cus­sions, we aim to pro­vide a com­pre­hen­sive under­stand­ing of the Aller­goOn­col­o­gy nexus, empha­siz­ing the impor­tance of pre­clin­i­cal mod­els, bio­mark­er research, and col­lab­o­ra­tive efforts in advanc­ing our knowl­edge and improv­ing patient out­comes in this intrigu­ing field.

This pre­sen­ta­tion delves into the fas­ci­nat­ing inter­sec­tion of aller­gy and oncol­o­gy, with a par­tic­u­lar focus on glioblas­toma. We will define the field of Aller­goOn­col­o­gy, describ­ing the cur­rent inter­face between aller­gol­o­gy and oncol­o­gy and dis­cussing var­i­ous path­ways involved in the asso­ci­a­tion between aller­gy and glioblastoma.

We will delve into our recent work demon­strat­ing the pro­tec­tive role of aller­gic air­way inflam­ma­tion against glioblas­toma pro­gres­sion in a murine mod­el, and its impli­ca­tions on sys­temic and local immu­ni­ty. Inves­ti­gat­ing how aller­gic inflam­ma­tion delays glioblas­toma pro­gres­sion in mice reveals intri­cate immune mech­a­nisms, includ­ing the tran­scrip­tion­al repro­gram­ming of microglia and the poten­ti­a­tion of local and adap­tive sys­temic immu­ni­ty (Doi: 10.1111/all.15545).

Addi­tion­al­ly, we will dis­cuss our col­lab­o­ra­tive efforts between the Euro­pean Acad­e­my of Aller­gy and Clin­i­cal Immunol­o­gy (EAACI) and the Euro­pean Asso­ci­a­tion of Neu­ro-Oncol­o­gy (EANO), aim­ing to refine the clas­si­fi­ca­tion of aller­gic dis­eases and gliomas for enhanced research in Aller­goOn­col­o­gy (Doi: 10.1111/all.15994).

Through these dis­cus­sions, we aim to pro­vide a com­pre­hen­sive under­stand­ing of the Aller­goOn­col­o­gy nexus, empha­siz­ing the impor­tance of pre­clin­i­cal mod­els, bio­mark­er research, and col­lab­o­ra­tive efforts in advanc­ing our knowl­edge and improv­ing patient out­comes in this intrigu­ing field.

AllergoOncology: Lessons Learned from the Allergy-Glioblastoma Connection
AllergoOncology: Lessons Learned from the Allergy-Glioblastoma Connection
AllergoOncology: Lessons Learned from the Allergy-Glioblastoma Connection

Aurélie Poli

High­ly ded­i­cat­ed and cre­ative sci­en­tist, my ambi­tion is to make break­through in deci­pher­ing how to cir­cum­vent glioma medi­at­ed local and sys­temic immuno­sup­pres­sion and to trans­late our dis­cov­er­ies into more effec­tive immunother­a­peu­tic strat­e­gy to sup­port patients’ outcomes.

In 2005, after obtain­ing my Master’s Degree in Biotech­nol­o­gy, I start­ed as a research engi­neer in Dr. J. Zim­mer group at the CRP-San­té, Lux­em­bourg, the pre­de­ces­sor to the Lux­em­bourg Insti­tute of Health, Lux­em­bourg (LIH). The research group inter­est focused on the biol­o­gy of Nat­ur­al Killer (NK) cells in both the con­text of TAP defi­cien­cy and their reg­u­la­tion by neu­rotroph­ic fac­tors. I devel­oped a strong back­ground in immunol­o­gy with a spe­cial­iza­tion in NK cell biology.

More about Dr. Aurélie Poli.

High­ly ded­i­cat­ed and cre­ative sci­en­tist, my ambi­tion is to make break­through in deci­pher­ing how to cir­cum­vent glioma medi­at­ed local and sys­temic immuno­sup­pres­sion and to trans­late our dis­cov­er­ies into more effec­tive immunother­a­peu­tic strat­e­gy to sup­port patients’ outcomes.

In addi­tion, through my active col­lab­o­ra­tion with mul­ti­ple inves­ti­ga­tors, I extend­ed my com­pe­tences to the fields of Aller­gol­o­gy, Oncol­o­gy and Neuro-Immunology.

Dur­ing this peri­od as engi­neer, I devel­oped a strong exper­tise in the func­tion­al and phe­no­typ­ic assess­ment of pri­ma­ry immune cells from mouse, rat and human, espe­cial­ly for NK cells and myeloid cells; with a demon­strat­ed exper­tise in using mul­ti-colour flow cytom­e­try and ex vivo co-cul­ture sys­tems. In 2010, I under­took a PhD the­sis at the doc­tor­al school of the Uni­ver­si­ty of Bergen in Nor­way, under the super­vi­sion of Prof. M. Chekenya, work­ing on the devel­op­ment of a new immunother­a­peu­tic strat­e­gy in rodent mod­els for its future trans­la­tion into the treat­ment of glioblas­toma (GBM) patients.

These stud­ies enabled me to acquire a strong back­ground in the field of neu­ro-immunol­o­gy as well as in brain tumour immunol­o­gy. Since 2015, I have been work­ing on imple­ment­ing Aller­goOn­col­o­gy research at LIH, with the sup­port of both Prof. M. Ollert, Direc­tor of the Depart­ment of Infec­tion and Immu­ni­ty (DII), and Prof S. Niclou, Direc­tor of the Depart­ment of Can­cer research (DoCR) at LIH. My research focus­es on the under­stand­ing of the epi­demi­o­log­i­cal asso­ci­a­tion between glioma devel­op­ment and a pre-exist­ing his­to­ry of allergy.

Since Feb­ru­ary 2021, I was strate­gi­cal­ly repo­si­tioned from DII to the DoCR by inte­grat­ing the Neu­ro-Immunol­o­gy Group head­ed by Dr Alessan­dro Micheluc­ci to con­duct and sup­port new as well as ongo­ing immune-relat­ed projects aimed at explor­ing and exploit­ing mol­e­c­u­lar path­ways to pro­mote and restore anti-tumoral fea­tures of myeloid cells in the con­text of GBM.

I am elect­ed board mem­ber of the Work­ing Group for Aller­goOn­col­o­gy, from the Euro­pean Acad­e­my of Aller­gy and Clin­i­cal Immunol­o­gy (EAACI). Fur­ther­more, since 2022, I am chair­ing a new­ly cre­at­ed inter­na­tion­al Task Force of the work­ing group for Aller­goOn­col­o­gy; spon­sored by the EAACI, on the top­ic of : “Aller­goOn­col­o­gy in the Era of Per­son­al­ized, Strat­i­fied and Pre­ci­sion Medicine”.

In 2005, after obtain­ing my Master’s Degree in Biotech­nol­o­gy, I start­ed as a research engi­neer in Dr. J. Zim­mer group at the CRP-San­té, Lux­em­bourg, the pre­de­ces­sor to the Lux­em­bourg Insti­tute of Health, Lux­em­bourg (LIH). The research group inter­est focused on the biol­o­gy of Nat­ur­al Killer (NK) cells in both the con­text of TAP defi­cien­cy and their reg­u­la­tion by neu­rotroph­ic fac­tors. I devel­oped a strong back­ground in immunol­o­gy with a spe­cial­iza­tion in NK cell biology.

In addi­tion, through my active col­lab­o­ra­tion with mul­ti­ple inves­ti­ga­tors, I extend­ed my com­pe­tences to the fields of Aller­gol­o­gy, Oncol­o­gy and Neuro-Immunology.

Dur­ing this peri­od as engi­neer, I devel­oped a strong exper­tise in the func­tion­al and phe­no­typ­ic assess­ment of pri­ma­ry immune cells from mouse, rat and human, espe­cial­ly for NK cells and myeloid cells; with a demon­strat­ed exper­tise in using mul­ti-colour flow cytom­e­try and ex vivo co-cul­ture sys­tems. In 2010, I under­took a PhD the­sis at the doc­tor­al school of the Uni­ver­si­ty of Bergen in Nor­way, under the super­vi­sion of Prof. M. Chekenya, work­ing on the devel­op­ment of a new immunother­a­peu­tic strat­e­gy in rodent mod­els for its future trans­la­tion into the treat­ment of glioblas­toma (GBM) patients.

These stud­ies enabled me to acquire a strong back­ground in the field of neu­ro-immunol­o­gy as well as in brain tumour immunol­o­gy. Since 2015, I have been work­ing on imple­ment­ing Aller­goOn­col­o­gy research at LIH, with the sup­port of both Prof. M. Ollert, Direc­tor of the Depart­ment of Infec­tion and Immu­ni­ty (DII), and Prof S. Niclou, Direc­tor of the Depart­ment of Can­cer research (DoCR) at LIH. My research focus­es on the under­stand­ing of the epi­demi­o­log­i­cal asso­ci­a­tion between glioma devel­op­ment and a pre-exist­ing his­to­ry of allergy.

Since Feb­ru­ary 2021, I was strate­gi­cal­ly repo­si­tioned from DII to the DoCR by inte­grat­ing the Neu­ro-Immunol­o­gy Group head­ed by Dr Alessan­dro Micheluc­ci to con­duct and sup­port new as well as ongo­ing immune-relat­ed projects aimed at explor­ing and exploit­ing mol­e­c­u­lar path­ways to pro­mote and restore anti-tumoral fea­tures of myeloid cells in the con­text of GBM.

I am elect­ed board mem­ber of the Work­ing Group for Aller­goOn­col­o­gy, from the Euro­pean Acad­e­my of Aller­gy and Clin­i­cal Immunol­o­gy (EAACI). Fur­ther­more, since 2022, I am chair­ing a new­ly cre­at­ed inter­na­tion­al Task Force of the work­ing group for Aller­goOn­col­o­gy; spon­sored by the EAACI, on the top­ic of : “Aller­goOn­col­o­gy in the Era of Per­son­al­ized, Strat­i­fied and Pre­ci­sion Medicine”.

Aurelie Poli | AllergoOncology: Lessons Learned from the Allergy-Glioblastoma Connection
Aurélie Poli, Lux­em­bourg Insti­tute of Health, LUXEMBOURG

Read the Abstracts from Our Invit­ed Speakers

Can­cer Biology

Can­cer Neuroscience

Can­cer Therapy

PORT for Busi­ness — Com­pa­ny Session